Tag Archives: MDVN

Top 5 Biotech Stocks To Buy Right Now

Related IBB Turing Rejects $100 Million Offer For Daraprim Rich Ross Is Bullish On The NASDAQ Biotech ETF The Vetr community has downgraded $IBB to 3-Stars (Vetr)
Related XLV With House Vote, Trump And GOP Cheer As Obamacare Officially Begins Roll-Back Process Assessing The Odds Of An ACA Repeal And Replace....More>>>

Top 5 Biotech Stocks To Invest In Right Now

It has not been a good year for Gilead Sciences (NSDQ:GILD) shareholders. Gilead stock is down bymore than 25% YTD and almost 30% in last one year. The stock has not only heavily underperformed the broader marketbut has also lagged the sector index iShares NASDAQ Biotech Index ETF (NSDQ:IBB) which is down nearly 17% YTD.The poor performance of the stock is mainly caused by declining HCV sales numbers.....More>>>

Top 10 Biotech Stocks To Own For 2018

Its time for the final push.

With only a handful of trading weeks remaining in 2017, little stands in the way of higher prices.

This years stock market melt-up has produced a long list of incredible winners. The FAANGs, semiconductors, and other big tech stocks have helped fuel the rally. Weve also had multiple chances to profit from the big biotech comeback and the rebirth of homebuilder....More>>>

Hot Biotech Stocks To Invest In 2018

Bio-Techne Corp (NASDAQ:TECH) files its latest 10-K with SEC for the fiscal year ended on June 30, 2017. Bio-Techne Corp and is a biotechnology company which develops, manufactures and sells biotechnology reagents, instruments and clinical diagnostic products. Bio-Techne Corp has a market cap of $4.5 billion; its shares were traded at around $120.62 with a P/E ratio of 62.16 and P/S ratio of 8.35.....More>>>

Top Biotech Stocks To Buy Right Now

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication.

Welcome to another edition of “3 Things In Biotech” a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.

Shire enters the home stretch with its newer formulation of asparaginase

Company: Shire....More>>>

Top 5 Biotech Stocks To Watch For 2019

The stock market finished mixed on Tuesday, and although the Dow Jones Industrials still finished with a loss of more than 100 points, other major market benchmarks finished very close to the unchanged level on the day. Geopolitical pressure continued to hurt investor sentiment, and some bad news on the earnings front also cast a pall on trading during the regular session. Yet some stocks managed....More>>>

Hot Biotech Stocks To Buy Right Now

On Tuesday, Baird predicted that Gilead Sciences (GILD) will miss earnings forecasts when it releases its financials on April 28. Barclays’ Geoff Meacham and team, however, foresee an earnings beat from Gilead and Amgen (AMGN) as well, but are more cautious on Biogen (BIIB) and Celgene (CELG). They explain why:


Large-Cap Biotechs Strength in Gilead and Amgen. We think....More>>>

Top 10 Biotech Stocks To Buy Right Now

The Dow Jones Industrial Average came close to hitting 20,000, but fell short again…nearly four weeks after Barron’s wrote about the possibility in a cover story on Dec. 10.

Getty Images

The S&P 500 rose 0.4% to 2,276.98 today, a record high. The Nasdaq Composite, meanwhile, gained 0.6% to 5,521.06, also a record. The Dow Jones Industrial Average advanced 64.51 points,....More>>>

Top Biotech Stocks To Invest In Right Now

Investment company Harbour Capital Advisors, LLC buys iShares Core MSCI Emerging Markets, iShares Core MSCI EAFE, PIMCO Enhanced Short Maturity Active Exchange-Trad, iShares Nasdaq Biotechnology Index Fund, First Republic Bank, Chubb, Andeavor, Moelis, Charles Schwab Corp, NetEase Inc, sells MetLife Inc, Affiliated Managers Group Inc, Microchip Technology Inc, Nike Inc, Wells Fargo during the 3-months....More>>>

Top 10 Biotech Stocks To Watch For 2018


On Dec. 15, 2017, the share of Omeros Corporation (NASDAQ:OMER) – a bioscience focusing on the innovation and commercialization of drugs to treat complement-mediated diseases, inflammation, and central nervous system disorders – appreciated $0.47 to trade at $19.68 for 3.52% profits (as of 2:47 pm ET). Since we featured the firm in the Integrated BioSci Interview with....More>>>